ZWZheng Wu

Zheng Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zheng Wu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Qi

    Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou 510095, China

    2 shared publications
  • Dong-Ping Chen

    Department of Radiation Oncology, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou 510095, China

    1 shared publication
  • En-Hao Yu

    Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiang Ya School of Medicine, Central South University, Changsha, People’s Republic of China

    1 shared publication
  • Fang Yang

    Department of Radiation Oncology, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou 510095, China

    1 shared publication
  • Fei-Fei Lin

    Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, People's Republic of China

    1 shared publication
  • Fei-Ping Li

    Department of Imaging, Hunan Cancer Hospital & the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Intratumoral and peritumoral habitat radiomics of MRI predicts pathologic complete response to neoadjuvant chemoimmunotherapy in oral squamous cell carcinoma

    by Zilong Yuan, Shuangquan Ai, Qian He, Kun Wu, Miao Yang, Kaiyi Zheng, Yaoyao He, Xiaojuan Tang, Yulin Liu, Zheng Wu, et al.

    Background: Neoadjuvant chemoimmunotherapy (NACI) shows promise in oral squamous cell carcinoma (OSCC), but reliable noninvasive biomarkers for predicting pathologic complete response (pCR) remain scarce. Radiomics integrating intratumoral and peritumoral heterogeneity across multi-sequence MRI may offer novel insights into treatment response evaluation. Methods: The data of 212 patients with OSCC after NACI were retrospectively collected and analyzed. Among these patients, 56 (26.4%) achieved pCR after NACI. Intratumoral and peritumoral habitat imaging (HI) was achieved using the K-means clustering algorithm applied to T1-weighted imaging (T1WI), axial T2-weighted imaging with fat suppression (T2WI), and contrast-enhanced T1-weighted imaging with fat suppression (T1C). Moreover, intratumoral and peritumoral HI models were constructed and compared using the receiver operating characteristic curve (ROC). Five-fold cross-validation was performed to mitigate model overfitting. Results: Intratumoral HI models derived from different sequences and the Intratumoral Fusion model exhibited favorable predictive ability, with AUCs of 0.738-0.817 and 0.729-0.789 in the training and testing cohorts, respectively. Moreover, peritumoral HI models displayed marginally higher predictive abilities compared to intratumoral HI and Fusion models, with AUCs of 0.734-0.869 and 0.788-0.802 in the training and testing cohorts, respectively. Meanwhile, the decision model with peritumoral habitat features (PHF S ), intratumoral habitat features (IHF S ), and 3 clinical features displayed the highest performance, with average AUCs of 0.913 and 0.843 in both respective cohorts. Among the most important features screened by SHAP, three IHFs and one PHF could effectively distinguish between the lower and higher groups of programmed cell death ligand 1 (PD-L1) Combined Positive Score (t = 2.027-2.275, P < 0.05), whilst two PHFs were highly correlated with CD45+ white blood cell densities in the stroma (r = 0.958, −0.920, P < 0.05), which were associated with pCR. Conclusions: Integrated intratumoral and peritumoral HI derived from multi-sequence MRI offers a high predictive capacity for pCR following NACI in OSCC patients.


  • Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions

    by Wen-Jing Yin, Wu Mao, Fang Yang, Meng-Yao Wang, Jin-Quan Liu, Dong-Ping Chen, Li-Ping Zhou, Si-Da Chen, Xi-Zhen Jiang, Yu-Meng Ou, et al.


  • Open Access

    Measurement of the distance between tumor micro-foci and gross tumor in rectal cancer pathological specimens: implication on margin distance of clinical target volume treated with high-dose radiotherapy for rectal cancer

    by Xu-Jie Bao, Xiao-Yan Chen, Lu Wen, Yuan-Yuan Liu, En-Hao Yu, Zheng Wu, Ke Liu, Ju-Mei Zhou, Su-Yu Zhu

    Purpose: To measure the micro-foci distance away from gross tumor and to provide reference to create the clinical target volume (CTV) margin for boost radiotherapy in rectal adenocarcinoma. Methods: Twenty-eight rectal cancer surgical specimens of only total mesorectal excision were collected. The pathological specimens were retrospectively measured, and the nearest distance between the tumor micro-foci and gross tumor was microscopically measured. The “in vivo–in vitro” retraction factor was calculated as the ratio of the deepest thickness laterally and the vertical height superior/inferiorly of the rectal tumor measured in MRI and those measured in immediate pathological specimens. The retraction factor during pathological specimen processing was calculated as the distance ratio before and after dehydration in the lateral, superior, and inferior sides by the “knot marking method.” The distances of tumor micro-foci were individually corrected with these two retraction factors. Results: The mean “in vivo–in vitro” tumor retraction factors were 0.913 peripherally and 0.920 superior/inferiorly. The mean tumor specimen processing retraction factors were 0.804 peripherally, 0.815 inferiorly, and 0.789 superiorly. Of 28 patients, 14 cases (50.0%) had 24 lateral micro-foci, 8 cases (28.6%) had 13 inferior micro-foci, and 7 cases (25.0%) had 19 superior micro-foci. The 95th percentiles of the micro-foci distance for 28 patients were 6.44 mm (peripheral), 5.54 mm (inferior), and 5.42 mm (superior) after retraction correction. Conclusion: The micro-foci distances of 95% of rectal adenocarcinoma patients examined were within 6.44 mm peripherally, 5.54 mm inferiorly, and 5.42 mm superiorly. These findings provide reference to set the boost radiotherapy CTV margin for rectal cancer.